Drug Profile
Diclofenac transdermal - Crescita Therapeutics
Alternative Names: Diclofenac sodium topical solution 2% w/w; MNK-395; NRI-1004; Pennsaid 2%; Pennsaid Gel; Pennsaid Plus; Pennsaid Viscous SolutionLatest Information Update: 06 Nov 2023
Price :
$50
*
At a glance
- Originator Nuvo Research
- Developer Gebro Pharma AG; Horizon Therapeutics plc; NovaMedica; Nuvo Research; Sayre Therapeutics
- Class Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Musculoskeletal pain
Most Recent Events
- 29 Nov 2022 No development reported - Preregistration for Musculoskeletal pain in Austria (Transdermal) (Crescita Therapeutics pipeline; November 2022)
- 29 Nov 2022 No development reported - Preregistration for Musculoskeletal pain in India (Transdermal) (Crescita Therapeutics pipeline; November 2022)
- 11 May 2020 Gebro Pharma anticipates the commercial launch of diclofenac transdermal in Switzerland in the fourth quarter of 2020